Education
About Us
Working with TipRanks
Follow Us
Generation Bio Co. (GBIO)
NASDAQ:GBIO
GBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $4.65
Previous CloseN/A
Volume226.22K
Average Volume (3M)448.68K
Market Cap
$33.71M
Enterprise Value$73.85M
Total Cash (Recent Filing)$37.71M
Total Debt (Recent Filing)$95.94M
Price to Earnings (P/E)―
Beta3.15
Next Earnings
May 01, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding67,007,866
10 Day Avg. Volume465,370
30 Day Avg. Volume448,679
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.69
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.71
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$7.33Price Target Upside1366.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Generation Bio News
PremiumCompany Announcements
Generation Bio Co. Advances in Autoimmune Therapeutics
PremiumCompany Announcements
Generation Bio Restructures Leadership and Focuses on siRNA---
Bulls Say, Bears Say
Bulls Say
CollaborationsGBIO continues to make progress in its collaboration with Moderna, aiming to synergize its internal work with T cells with Moderna’s ctLNPs application to CAR T cell development.
Strategic DevelopmentsSuccessfully delivering mRNA directly into T-cells could differentiate Generation Bio Co. from competitors, who primarily target the liver.
Technological InnovationGeneration Bio Co. is focusing on innovative siRNA therapeutics for autoimmune disorders, which could set them apart in the market.
Bears Say
Market ValuationThe stock is currently trading below its cash position, which is viewed as a fair discount consistent with other biotech companies with similar uncertainties.
Uncertainty In Product DevelopmentMore details on the lead indication are needed to better assess the model, so the current recommendation is maintained as is for now.
---
Ownership Overview
17.72% Insiders
23.14% Mutual Funds
26.37% Other Institutional Investors
25.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GBIO FAQ
What was Generation Bio Co.’s price range in the past 12 months?
Generation Bio Co. lowest stock price was $0.47 and its highest was $4.65 in the past 12 months.
What is Generation Bio Co.’s market cap?
Generation Bio Co.’s market cap is $33.71M.
When is Generation Bio Co.’s upcoming earnings report date?
Generation Bio Co.’s upcoming earnings report date is May 01, 2025 which is in 36 days.
How were Generation Bio Co.’s earnings last quarter?
Generation Bio Co. released its earnings results on Mar 13, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.301 by -$0.019.
Is Generation Bio Co. overvalued?
According to Wall Street analysts Generation Bio Co.’s price is currently Undervalued.
Does Generation Bio Co. pay dividends?
Generation Bio Co. does not currently pay dividends.
What is Generation Bio Co.’s EPS estimate?
Generation Bio Co.’s EPS estimate is -0.29.
How many shares outstanding does Generation Bio Co. have?
Generation Bio Co. has 67,007,866 shares outstanding.
What happened to Generation Bio Co.’s price movement after its last earnings report?
Generation Bio Co. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.301. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Generation Bio Co.?
Currently, no hedge funds are holding shares in GBIO
---
Generation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.33 (1366.00% Upside)
$7.33 (1366.00% Upside)
Hedge Fund Trend
Decreased
By 3.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $203.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.94%
12-Months-Change
Fundamentals
Return on Equity
-91.02%
Trailing 12-Months
Asset Growth
-38.31%
Trailing 12-Months
Company Description
Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
---
GBIO Stock 12 Month Forecast
Average Price Target
$7.33
▲(1366.00% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering GBIO
1 Year
---